Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

The aim of the present work is to compare drug survival and safety of infliximab, etanercept, and adalimumab (tumor necrosis factor [TNF] antagonists) in spondylarthritis (SpA) with those of rheumatoid arthritis (RA). To this purpose, we analysed the data in BIOBADASER (2000–2005), a drug registry l...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmona, Loreto, Gómez-Reino, Juan J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526631/
https://www.ncbi.nlm.nih.gov/pubmed/16620398
http://dx.doi.org/10.1186/ar1941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526631/
https://www.ncbi.nlm.nih.gov/pubmed/16620398
http://dx.doi.org/10.1186/ar1941

Ejemplares similares